Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial.
about
Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysisPharmacology of estrogens and progestogens: influence of different routes of administrationReproductive history, hormone replacement, and incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology.Prevention and treatment of venous thromboembolism during HRT: current perspectives.Hormonal contraception and thrombotic risk: a multidisciplinary approach.Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study.The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?Preanalytical conditions that affect coagulation testing, including hormonal status and therapy.Hormones and pregnancy: thromboembolic risks for women.Hormone replacement therapy and peripheral vascular disease in women.DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-based drug repurposing.Clinical appraisal of the Women's Health Initiative.Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women.Hormone replacement therapy in menopausal women: Past problems and future possibilities.Vascular and metabolic effects of sex steroids: new insights into clinical trials.Postmenopausal hormone therapy and the risk of venous thromboembolism.Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen.Transdermal hormone therapy in postmenopausal women: a review of metabolic effects and drug delivery technologies.Hormone therapy and risk of venous thromboembolism among postmenopausal women.What's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone.Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone.Estrogen and progestogen effect on venous thromboembolism in menopausal women.Hormones and venous thromboembolism among postmenopausal women.Thrombotic issues in transgender medicine: A review.The differential association of conjugated equine estrogen and esterified estrogen with activated protein C resistance in postmenopausal women.Coronary heart disease in women: what do we know now?The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy.Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women.Parenteral administration of progestins for hormonal replacement therapy.Role of inflammatory cytokines in the effect of estradiol on atheroma.How to stay heart healthy in 2011: considerations for the primary prevention of cardiovascular disease in women.
P2860
Q24647720-806AE7CD-1A9A-485B-B690-0B4111BE6EE6Q28268346-6FD535C8-9187-45F2-A5D3-C0A47164BD25Q33828936-94E24BAF-5ECF-4C00-80BD-E8976112E4F8Q34140721-1A47BEFA-9656-4889-92B7-5B0C667D3991Q34513007-EF30BA26-1624-41D0-983B-9C6F89B4CE34Q34627034-9D5C830E-6F55-4B94-9F32-A5EA422059D4Q34932849-DBFAF3A1-4DDF-4E6F-82CF-42D4B5D91596Q35839837-7FFEBCCC-7FA5-4762-B76B-F0403946F7BEQ35852845-C8F7559C-1938-49C9-AAEC-FA5AA052C148Q35981132-04C3E1C6-6E87-44C3-ABE5-D085D5029891Q36010298-00433DC8-99B2-4BA1-81AA-C2C9CA040E18Q36072505-85C68339-4D00-421F-9499-B87C305D06F6Q36570589-0094A940-7325-4DCE-A8B6-57E76987192FQ36668526-C37FF925-09DB-48AB-878A-6ABE91AC48CEQ36888620-4E1C615D-3208-409F-B8FF-4F85FE231F15Q37223479-929CA3AA-D76B-4339-8758-CCDB67C3CB35Q37338824-5743DA36-AB52-477B-9B51-1F98B21AB33EQ37385612-BC179109-8177-4F0F-A42B-B75873951F2DQ37610399-236118E9-38A1-4347-92F1-8BD69C29840BQ37995320-09F67B5A-48A8-46F8-BF3C-B1D725444ED5Q37995321-83A31FA0-C5DC-42D1-8590-FBEBE0034FDDQ38011781-EBB1679F-B6E7-40F1-AD97-84B20A3D99FBQ38249888-BF514F1E-CCB7-484A-967A-645040FE1E03Q38990294-2D18BE15-4803-401A-B93C-A9DA3A64B1BBQ39347912-7D732824-AE6C-4BB8-B415-9047AFC60FB9Q40393652-B1AB99BF-D9D4-4CBD-9925-2C7EB0E53035Q43018685-0B702BD2-39B8-4278-9215-9CC69B7329FDQ43494908-3871E88F-674E-4563-BAA9-CC4BCFB491A5Q46064377-09594CFE-6B2B-4095-83B3-4F3F0704A86EQ46727875-AD68415B-3858-4CB0-BD46-5CD8F9CB253DQ46755958-0DE794EB-D615-4A0F-9D68-B26101BFC957
P2860
Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Differential effects of oral a ...... sal women: a randomized trial.
@en
Differential effects of oral a ...... sal women: a randomized trial.
@nl
type
label
Differential effects of oral a ...... sal women: a randomized trial.
@en
Differential effects of oral a ...... sal women: a randomized trial.
@nl
prefLabel
Differential effects of oral a ...... sal women: a randomized trial.
@en
Differential effects of oral a ...... sal women: a randomized trial.
@nl
P2093
P1476
Differential effects of oral a ...... sal women: a randomized trial.
@en
P2093
Dominique Mottier
Emmanuel Oger
Jean-François Abgrall
Karine Lacut
Marie-Thérèse Blouch
Martine Aiach
Martine Alhenc-Gelas
Michel Collet
Nathalie Roudaut
Pierre-Yves Scarabin
P304
P356
10.1161/01.ATV.0000087141.05044.1F
P407
P577
2003-07-17T00:00:00Z